Nanologica has received an order for the company’s silica-based purification media NLAB Saga® from a new customer in the US. The customer is a manufacturer of peptide drugs, and the order relates to evaluation of NLAB Saga® on a production scale.
This is Nanologica’s first order in the North American market for evaluation of the company’s silica at production scale. The order value is USD 140,700, which corresponds to appx. SEK 1.3 million at today’s exchange rate.
“This is an important order for us as it means that we are now taking a step into the North American market. So far, our main focus has been on markets in Asia, especially China, where we have taken recurring production orders for NLAB Saga®. It is therefore very gratifying that we are now getting started in the US as well”, Nanologica’s CEO Andreas Bhagwani comments.
The order will be delivered during the third quarter.